Does IgG or complement reactivity to zonulin or occludin establish intestinal permeability?

Intestinal “barrier” blood panels are often interpreted as evidence of “leaky gut,” but the available evidence does not support that conclusion from zonulin- or occludin-directed IgG/complement reactivity alone.

Clinical and assay interpretation

• IgG reactivity to zonulin or occludin, including results accompanied by complement markers such as C3d, has not been validated against an independent functional permeability reference standard. No prospective diagnostic-accuracy evidence provides sensitivity, specificity, predictive values, or ROC performance versus urinary lactulose–mannitol testing.
• Commercial zonulin assays raise additional concerns: some may detect proteins other than zonulin/pre-haptoglobin-2, and detectable results in individuals unable to produce pre-haptoglobin-2 challenge analyte specificity. Reported commercial zonulin and serum ZO-1-related measures have shown poor correlation with lactulose–mannitol testing.
• Accordingly, such antibody/complement findings are not diagnostic proof of increased intestinal permeability or tight-junction dysfunction.

Stool inflammation markers

• Normal fecal calprotectin—often below a commonly used 50 µg/g cutoff—makes active neutrophil-associated intestinal inflammation and, in an appropriate clinical setting, inflammatory bowel disease less likely.
• This is clinically reassuring but not definitive: the negative predictive value depends on the assay and pretest probability.
• Calprotectin reflects neutrophil-associated mucosal inflammation, not epithelial permeability. A normal value therefore cannot demonstrate an intact intestinal barrier or normal permeability, though it can temper concern that the antibody result represents ongoing inflammatory gut disease.

IgA and mechanistic context

• Normal IgA reactivity has no validated independent predictive or exclusionary role in interpreting zonulin/occludin IgG or complement reactivity. There are no established standards for interpreting these markers as a combined pattern.

Bottom line

• IgG/complement reactivity to zonulin or occludin should not be treated as evidence of intestinal permeability. Normal inflammatory stool markers reduce the likelihood of active inflammatory bowel disease but do not settle permeability, while normal IgA currently does not meaningfully validate or negate the blood-panel finding.